Subhashis Banerjee, MD
About Subhashis Banerjee, MD
Subhashis Banerjee, MD, is the Vice President at Bristol Myers Squibb with nearly three decades of experience in autoimmune and inflammatory disorders.
Current Title and Company
Subhashis Banerjee currently holds the position of Vice President at Bristol Myers Squibb in Princeton, New Jersey, United States.
Professional Experience
Subhashis Banerjee has amassed extensive experience in the pharmaceutical industry and academia. He served as Senior Director at Eli Lilly and Company from 2009 to 2013 in Indianapolis, Indiana. Prior to that, he was the Director at Pfizer between 2005 and 2009 in New Haven, Connecticut. Earlier in his career, he spent 12 years at AbbVie as a Senior Principal Scientist in Worcester, Massachusetts. His initial hands-on experience in the medical field began as a Resident Doctor at St. Vincent Hospital in Worcester, Massachusetts, from 2002 to 2004.
Educational Background
Subhashis Banerjee obtained his Doctor of Medicine (MD) with a specialization in Internal Medicine Residency Program from Christian Medical College and Hospital. He also holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Christian Medical College Vellore. Additionally, he completed an Internal Medicine Residency Program at St. Vincent Hospital, Worcester, MA.
Clinical Program Leadership
Subhashis Banerjee has notably designed and led the entire POETYK clinical program for deucravacitinib, focusing on psoriasis and other multiple indications. His leadership played a critical role in regulatory submissions globally, leading to the approval of deucravacitinib in the US, EU, Japan, and other countries.
Publications and Patents
Subhashis Banerjee has authored numerous publications in prestigious journals, including the New England Journal of Medicine, Arthritis & Rheumatology, Annals of Rheumatic Diseases, the Journal of American Academy of Dermatology, the Journal of Clinical Investigation, Nature, Cell, and Immunity. In addition, he holds several patents in the field of autoimmune and inflammatory disorders.
Expertise in Autoimmune and Inflammatory Disorders
With nearly three decades of experience, Subhashis Banerjee has played key roles in the development of immunomodulatory compounds such as adalimumab (Humira R), briakinumab, tofacitinib (Xeljanz R), and ixekizumab (Taltz R). His extensive background spans both industry and academic settings.